Lipocine Inc. (LPCN) Stock Price & Analysis
Lipocine Inc. (LPCN) rose 0.49% to USD 2.05 as of June 10, 2026 at 09:04 UTC, according to Nexqual real-time market data.
LPCN last closed at USD 2.04; the session ranged USD 2.01–2.11 on volume of 95,892 shares. Market capitalization is $16.90M, with a 52-week range of USD 1.81–12.37 (NCM). Source: Nexqual, June 10, 2026 at 09:04 UTC.
Key Statistics (as of June 10, 2026 at 09:04 UTC)
| Price | USD 2.05 |
|---|---|
| Change | ▲ 0.49% (up) |
| Previous Close | USD 2.04 |
| Open | USD 2.04 |
| Day Range | USD 2.01 – 2.11 |
| 52-Week Range | USD 1.81 – 12.37 |
| Volume | 95,892 shares |
| Market Cap | $16.90M |
| Exchange | NCM |
Technical Analysis (LPCN)
Nexqual's technical model rates LPCN "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 09:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 30.22 (neutral) |
| vs SMA50 | Below (USD 2.74) |
| MACD | -0.21 (negative) |
Analyst Ratings (LPCN)
Wall Street analysts rate LPCN "None" based on 1 analysts, with a mean price target of USD 6 (range USD 6–6), per Nexqual as of June 10, 2026 at 09:04 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 6 |
| High Target | USD 6 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 1 / 1 / 0 |
Earnings (LPCN)
| Revenue Estimate | $213,000 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.54 vs est -0.49 ▼ miss |
| 2025-12-31 | USD -0.42 vs est -0.61 ▲ beat |
| 2025-09-30 | USD -0.59 vs est -0.54 ▼ miss |
| 2025-06-30 | USD -0.41 vs est -0.4 ▼ miss |
Source: Nexqual, June 10, 2026 at 09:04 UTC.
Financials & Fundamentals (LPCN)
| Total Revenue | $2.00M |
|---|---|
| Revenue Growth (YoY) | +27.20% |
| Gross Margin | +100.00% |
| Operating Margin | -3224.09% |
| Profit Margin | +0.00% |
| ROE | -54.41% |
| Current Ratio | 9.99 |
| Total Cash | $24.73M |
| Total Debt | $0 |
| Free Cash Flow | $-5.96M |
Source: Nexqual, June 10, 2026 at 09:04 UTC.
Financial Health Score (LPCN)
Nexqual rates Lipocine Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 09:04 UTC.
| Growth | Critical — Revenue -82% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $25M cash, no debt |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Critical — ROE -54%, ROA -33.1% |
Ownership (LPCN)
| Insider Ownership | +4.51% |
|---|---|
| Institutional Ownership | +44.29% |
| Shares Outstanding | 8.24M |
| Float | 6.88M |
| Short % of Float | +1.12% |
Source: Nexqual, June 10, 2026 at 09:04 UTC.
Leadership (LPCN)
Lipocine Inc. is led by Mahesh V. Patel (age 68), Co-Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 09:04 UTC.
| Co-Founder, President, CEO & Director | Mahesh V. Patel (age 68) |
|---|---|
| Senior Vice President of Research & Development | Nachiappan Chidambaram (age 56) |
| Vice President of Sales, Marketing & Operations | Logan Morse (age 55) |
| Chief Medical Director | Anthony DelConte M. D. (age 67) |
Major Backers & Investors (LPCN)
Notable institutional backers of Lipocine Inc. include Ikarian Capital, LLC, Squadron Capital Management LLC, Eversept Partners, LP, according to Nexqual as of June 10, 2026 at 09:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ikarian Capital, LLC | 6.17% |
| Squadron Capital Management LLC | 5.46% |
| Eversept Partners, LP | 3.58% |
| Rosalind Advisors, Inc. | 2.69% |
| AIGH Capital Management LLC | 2.43% |
| Stempoint Capital LP | 1.95% |
| Boothbay Fund Management, LLC | 1.7% |
| Seven Fleet Capital Management LP | 1.52% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.86% |
Source: Nexqual, June 10, 2026 at 09:04 UTC.
From Lipocine Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- In 2025 and 2024, we spent $8.6 million and $7.4 million, respectively, on research and development.   Competition   Neuroactive Steroids Market overview   The unique potential mechanism of action ("MOA") of NAS presents an opportunity to treat a variety of CNS disorders.
- Our proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options.
- We will also continue efforts to enter into partnership arrangements for the continued development and/or marketing of LPCN 1144, LPCN 1148, LPCN 2401, LPCN 1107 as well as for the TRT Assets outside of the Currently Licensed TLANDO Territories.   Our products are based on our proprietary drug delivery technology platform.
- We intend to focus on the development of endogenous neuroactive steroids ("NASs") which have broad applicability in treating various CNS conditions where we can leverage our technology platform to develop highly differentiated oral therapeutics.
Partnerships
- On January 31, 2024, our license agreement with the former licensee (the "Antares License Agreement"), Antares Pharma, Inc. ("Antares"), was terminated and the transition of the U.S. commercial rights for TLANDO from Antares to Verity was completed on February 1, 2024, for the distribution, marketing and sale of TLANDO.
- We are also eligible to receive milestone payments of up to $259 million in the aggregate, depending on the achievement of certain sales milestones in a single calendar year and/or development milestones with respect to products licensed by Verity under the Verity License Agreement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DARE | Dare Bioscience, Inc. | USD 1.92 | ▲ 2.13% |
| FBIO | Fortress Biotech, Inc. | USD 2.93 | ▲ 10.57% |
| SCYX | SCYNEXIS, Inc. | USD 4.36 | ▼ 7.43% |
| VTGN | VistaGen Therapeutics, Inc. | USD 0.54 | ▼ 0.41% |
| CLRB | Cellectar Biosciences, Inc. | USD 2.36 | ▼ 8.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:04 UTC. This page is informational and not investment advice.